X4 Pharmaceuticals (XFOR) EBT Margin (2018 - 2025)
X4 Pharmaceuticals (XFOR) reported EBT Margin of 931.66% for Q4 2025, up 182727.0% on a YoY basis from N/an in Q4 2024, and up 44.9% quarter-over-quarter from 1690.93% in Q3 2025.
X4 Pharmaceuticals (XFOR) EBT Margin (2018 - 2025) Analysis & Trends
X4 Pharmaceuticals has reported EBT Margin for 4 years, with the latest figure at 931.66% in Q4 2025.
- For the quarter ending Q4 2025, EBT Margin rose 182727.0% year-over-year to 931.66%; the trailing twelve-month figure through Dec 2025 stood at 225.44% (up 122705.0% YoY), and the FY2025 full-year result was 225.44%, up 122705.0% from the prior year.
- EBT Margin for Q4 2025 stood at 931.66%, up from 1690.93% in the prior quarter.
- The five-year high for EBT Margin was 16136.94% in Q2 2024, with the low at 6550.18% in Q3 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 719,706.53 Bn | 719,706.50 Bn | - | - |
| 2 | Belite Bio | 55,800.00 Bn | 55,800.00 Bn | - | - |
| 3 | Quantum Biopharma | 18,182.30 Bn | 18,182.29 Bn | - | - |
| 4 | Legend Biotech | 3,154.00 Bn | 3,153.71 Bn | 242.10 Mn | 6.40% |
| 5 | Akari Therapeutics | 1,844.30 Bn | 1,844.29 Bn | - | - |
| 6 | Evaxion A | 1,567.96 Bn | 1,567.94 Bn | - | - |
| 7 | Psyence Biomedical | 251.43 Bn | 251.42 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 112.56 Bn | 105.31 Bn | 2.59 Bn | 41.95% |
| 9 | Abivax | 94.37 Bn | 94.37 Bn | - | - |
| 10 | X4 Pharmaceuticals | 156.06 Mn | 156.06 Mn | 2.20 Mn | -931.66% |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -931.66% |
| Sep 30, 2025 | -1,690.93% |
| Jun 30, 2025 | -1,302.79% |
| Mar 31, 2025 | 1.10% |
| Dec 31, 2024 | -2,758.93% |
| Sep 30, 2024 | -6,550.18% |
| Jun 30, 2024 | 16,136.94% |
| Mar 31, 2020 | -366.33% |
| Dec 31, 2018 | -235.46% |